The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Acadia Pharmaceuticals Inc shares valued at $243,114 were sold by Schneyer Mark C. on Nov 18 ’25. At $23.69 per share, Schneyer Mark C. sold 10,262 shares. The insider’s holdings dropped to 53,338 shares worth approximately $1.43 million following the completion of this transaction.
Also, Kihara James sold 4,084 shares, netting a total of over 96,754 in proceeds. Following the sale of shares at $23.69 each, the insider now holds 25,058 shares.
Before that, Daly James M had sold 30,000 shares from its account. In a trade valued at $670,983, the Director traded Acadia Pharmaceuticals Inc shares for $22.37 each. Upon closing the transaction, the insider’s holdings decreased to 30,000 shares, worth approximately $0.11 million.
As published in their initiating research note from Citigroup on October 21, 2025, Acadia Pharmaceuticals Inc [ACAD] has been a Buy and the price target has been revised to $33. Analysts at Deutsche Bank upgraded the stock from ‘”a Hold”‘ to ‘”a Buy”‘ outlook in a report released in late May. As of February 11, 2025, Deutsche Bank has initiated its “Hold” rating for ACAD. Earlier on January 03, 2025, Guggenheim downgraded its rating. Their new recommendation was “a Neutral” for ACAD stock which previously was a “a Buy”.
Analyzing ACAD Stock Performance
On last trading session, Acadia Pharmaceuticals Inc [NASDAQ: ACAD] plunged -0.30% to $26.81. The stock’s lowest price that day was $26.5501, but it reached a high of $27.065 in the same session. During the last five days, there has been a surge of approximately 3.59%. Over the course of the year, Acadia Pharmaceuticals Inc shares have jumped approximately 55.15%. Shares of the company reached a 52-week high of $27.73 on 12/08/25 and a 52-week low of $13.40 on 04/09/25.
Support And Resistance Levels for Acadia Pharmaceuticals Inc (ACAD)
According to the 24-hour chart, there is a support level at 26.55, which, if violated, would cause prices to drop to 26.29. In the upper region, resistance lies at 27.07. The next price resistance is at 27.32. RSI (Relative Strength Index) is 68.48 on the 14-day chart, showing neutral technical sentiment.
Is Acadia Pharmaceuticals Inc subject to short interest?
Stocks of Acadia Pharmaceuticals Inc saw a sharp rise in short interest on 2025-11-28 jumping by 0.4 million shares to 8.91 million. Data from Yahoo Finance shows that the short interest on 2025-10-31 was 8.51 million shares. A jump of 4.46% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 5.63 of the overall float, the days-to-cover ratio (short ratio) jumped to 5.63.
Which companies own the most shares of Acadia Pharmaceuticals Inc (ACAD)?
In terms of Acadia Pharmaceuticals Inc share price expectations, FactSet research, analysts set an average price target of 29 in the next 12 months, up nearly 7.85% from the previous closing price of $26.89. Analysts anticipate Acadia Pharmaceuticals Inc stock to reach 35 by 2025, with the lowest price target being 22. In spite of this, 16 analysts ranked Acadia Pharmaceuticals Inc stock as Buy at the end of 2025.
